This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QHE865. CME/AAPA credit will be available until February 21, 2025.Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSantosh L. Saraf, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agios Pharmacueticals, Inc.; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk, Inc.; and Pfizer.Grant/Research Support from Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.